Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa-5 + interferon alfa-2b (Digna Biotech S.L.)
- Development stage
- Unknown
- Lead developer
- Digna Biotech
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
interferon alfa-5 + interferon alfa-2b is an investigational biologic combination therapy consisting of two recombinant Type I interferon subtypes. Developed by Digna Biotech S.L. in collaboration with the Center for Applied Medical Research (CIMA) at the University of Navarra, the combination was designed to enhance the antiviral response in patients with chronic hepatitis C. The mechanism of action involves binding to the Type I interferon receptor (IFNAR), which triggers the JAK-STAT signaling pathway and leads to the transcription of interferon-stimulated genes (ISGs) that inhibit viral replication. A Phase I/II clinical trial (NCT01121731) evaluated the safety and efficacy of this combination in treatment-experienced patients with genotype-1 chronic hepatitis C, but no recent development has been reported since the trial's completion in 2012.
- Other names
- interferon-α5 + interferon-α2bIFN-α5 + IFN-α2b
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on interferon alfa-5 + interferon alfa-2b (Digna Biotech S.L.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa-5 + interferon alfa-2b (Digna Biotech S.L.).